SVCM
RAPP

Saturn V Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Saturn V Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70,000
Closed -$1.63M – 29
2024
Q2 		$1.63M Buy
+70,000
New +$1.62M 0.62% 24

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Saturn V Capital Management's RAPP Position: Q3 2024 in Review

Saturn V Capital Management sold out of Rapport Therapeutics (RAPP) in Q3 2024, closing a stake of 70,000 shares — an estimated $1.63M sold.

Saturn V Capital Management first reported a position in RAPP in Q2 2024 and held it in 1 quarter. The position peaked at $1.63M in Q2 2024. 55 funds tracked by Wall St. Rank hold RAPP as of Q3 2024.

  • Saturn V Capital Management reported no remaining Rapport Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 70,000 Rapport Therapeutics shares in Q3 2024, an estimated $1.63M.
  • Saturn V Capital Management first reported a position in Rapport Therapeutics in Q2 2024 and held it in 1 quarter.
  • Saturn V Capital Management's Rapport Therapeutics position peaked at $1.63M in Q2 2024.
  • 55 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2024.

Based on Saturn V Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.